# Use of Sitagliptin to Decrease Microalbuminuria

Study · id `cardio:ct-nct02048904` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02048904](<https://clinicaltrials.gov/study/NCT02048904>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02048904

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.

## Technical summary

Registry record NCT02048904. Randomized; double masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2017-08-10.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT02048904, source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT02048904, source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)
- Primary completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02048904, source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT02048904, source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)
- Results first posted: 2017-08-10 (ClinicalTrials.gov record NCT02048904, source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02048904, source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02048904-2017-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of Sitagliptin to Decrease Microalbuminuria
- Condition: Type 2 Diabetes
- Condition: Microalbuminuria
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Placebo
- Lead sponsor: University of Missouri-Columbia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: c455362e8bfa5e9c5489e463bc77fae9554355578d07e2c86928d0ffc0340724
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
